Tarenflurbil

Source: Wikipedia, the free encyclopedia.
Tarenflurbil
Clinical data
ATC code
  • none
Legal status
Legal status
Identifiers
  • (R)-2-(3-Fluoro-4-phenylphenyl)propanoic acid
JSmol)
  • Fc2cc(ccc2c1ccccc1)[C@H](C(=O)O)C
  • InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)/t10-/m1/s1 ☒N
  • Key:SYTBZMRGLBWNTM-SNVBAGLBSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Tarenflurbil,

NSAID flurbiprofen. For several years, research and trials for the drug were conducted by Myriad Genetics, to investigate its potential as a treatment for Alzheimer's disease; that investigation concluded in June 2008 when the company announced it would discontinue development of the compound.[2]

Mechanism of action

At proposed therapeutic concentrations, this molecule lacks anti-inflammatory activity, and does not inhibit either

beta amyloid,[3][4] the main constituent of amyloid plaques in Alzheimer's disease
, and therefore there was interest in this drug as a therapeutic agent.

Clinical trials

In 2005, Myriad Genetics reported the results of its Phase II clinical trial of Flurizan; it was the largest ever Alzheimer's drug treatment trial using R-flurbiprofen.[5] Patients were split into three treatment groups, receiving placebo, 400 or 800 mg R-flurbiprofen twice daily for a year. Result from this trial showed that the drug was well tolerated, and positive trends were observed with the 800 mg twice-daily dose in patients with mild Alzheimer's disease. A subgroup of patients that were diagnosed with mild disease, and had high plasma drug levels had significantly less decline in two primary behavioral outcomes (Activities of Daily Living scale (ADCS-ADL) and Global Function (CDR-SB)). Approximately 80 patients enrolled in the optional follow-on study showed continuing benefits with R-flurbiprofen, with increasing positive trends over this period for all primary outcomes after 24 months. On March 5, 2007 Myriad reported final results of the two-year trial, showing that 42% of those 80 patients showed improvement or no decline in one or more of the three primary endpoints of cognition, global function and activities of daily living, compared to a typical 10% of patients on placebo.

A

write-down.[2][7]

References

  1. ^ www.myriad.com Archived 2007-08-02 at the Wayback Machine Update on Flurizan.
  2. ^ a b c Myriad Genetics Reports Results of U.S. Phase 3 Trial of Flurizan in Alzheimer's Disease from the Myriad Genetics website.
  3. PMID 12897211
    .
  4. S2CID 33985910
    .
  5. ^ Myriad Genetics Reports Results of Phase 2 Trial of Flurizan in Patients With Alzheimer's Disease, a May 2005 article from the website of Myriad Genetics
  6. ^ www.myriad.com Archived 2006-03-16 at the Wayback Machine FLURIZAN & Alzheimer's Disease
  7. Mary Ann Liebert, Inc.
    2008-06-15. p. 8.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Tarenflurbil&oldid=1215175125"